What is CTI Life Sciences Fund?
CTI Life Sciences Fund operates as a prominent Canadian biotech venture capital firm, dedicated to transforming innovative ideas and assets into scalable biotechnology companies. With over two decades of operational experience, the firm has a robust track record, having executed more than 30 investments. Their investment thesis centers on therapeutic modalities across oncology, cardiology, and rare diseases, aiming for both long-term value creation and efficient exit strategies. CTI's commitment extends to fostering growth within the local innovation ecosystem while delivering life-saving therapies.
How much funding has CTI Life Sciences Fund raised?
CTI Life Sciences Fund has raised a total of $125M across 2 funding rounds:
Other Financing Round
$25M
Other Financing Round
$100M
Other Financing Round (2006): $25M with participation from FIER Partners
Other Financing Round (2012): $100M led by FIER Partners
Key Investors in CTI Life Sciences Fund
FIER Partners
FIER Partners is a platform focused on technology, culture, finance, and lifestyle, offering insights and resources for professionals and entrepreneurs. They provide information on financial trends and marketing advice, aiming to foster continuous learning and growth.
What's next for CTI Life Sciences Fund?
The recent major strategic investment signifies a pivotal moment for CTI Life Sciences Fund, likely enabling the acceleration of its portfolio companies' development pipelines and market penetration strategies. This capital infusion is expected to bolster CTI's capacity to identify and nurture early-stage biotech ventures, further solidifying its role as a key player in advancing medical treatments and generating substantial returns for its investors. The firm's continued focus on expedited exit strategies suggests a dynamic approach to portfolio management and a commitment to realizing value for all stakeholders.
See full CTI Life Sciences Fund company page
